Australia Federal Court Dismisses Cancer Patients' Challenge to Myriad's Gene Patent | GenomeWeb

NEW YORK (GenomeWeb News) – The Federal Court of Australia has dismissed a case in which a group of cancer patients were challenging the viability of a patent held by Myriad Genetics covering mutations in the BRCA1 gene linked to increased risk of hereditary breast and ovarian cancer.

Under Australian patent law, human beings and the biological processes involved in the creation of human beings are not patentable, but any "manner of manufacture," claims that are novel, inventive and useful, are patentable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.